Abstract 732: Iron oxide nanoparticles functionalized with the Clostridium Perfringens Enterotoxin carboxi-terminal fragment peptide: A novel diagnostic and therapeutic approach to specifically target ovarian cancer.

Author(s):  
Emiliano Cocco ◽  
Ileana Bortolomai ◽  
Stefania Bellone ◽  
Sara Gasparrini ◽  
Diana English ◽  
...  
BMC Cancer ◽  
2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Emiliano Cocco ◽  
Francesca Casagrande ◽  
Stefania Bellone ◽  
Christine E Richter ◽  
Marta Bellone ◽  
...  

2016 ◽  
Vol 4 (1) ◽  
pp. 159-166 ◽  
Author(s):  
Wenting Liu ◽  
Liju Nie ◽  
Fulai Li ◽  
Zoraida P. Aguilar ◽  
Hong Xu ◽  
...  

An effective method for separation and detection of ovarian cancer cells from whole blood using folic acid conjugated magnetic nanoparticles.


2016 ◽  
Vol 4 (47) ◽  
pp. 7741-7748 ◽  
Author(s):  
Li Zhao ◽  
Hongkuan Yang ◽  
Tsukuru Amano ◽  
Hongmei Qin ◽  
Luyi Zheng ◽  
...  

Chlorin e6, loaded on the surface of SPION-PG-Lys8 through electrostatic attraction, was delivered preferentially into mitochondria of SKOV3 ovarian cancer cells, improving efficacy of photodynamic therapy significantly.


Nanomedicine ◽  
2019 ◽  
Vol 14 (24) ◽  
pp. 3177-3191
Author(s):  
Kurtulus Gokduman

Aim: To investigate potential of magnetite iron oxide nanoparticles (MION) to sensitize cisplatin-resistant ovarian cancer cells to cisplatin, which to the best of found knowledge has not been reported previously. Materials & methods: MION with a diameter of approximately 20 nm were synthesized, and characterized using Fourier transform infrared spectroscopy, powder x-ray diffraction and particle size analyzer. Results: The synthesized MION have increased reactive oxygen species levels and decreased glutathione levels in cisplatin-resistant ovarian cancer cells (OVCAR-3 and SKOV-3). Using MTT, capsase-3 activity and live/dead assays, capability of the synthesized MION to sensitize cisplatin-resistant ovarian cancer cells has been illustrated. Conclusion: Thus, for further investigations, the synthesized MION can be considered as a potent agent enabling much more effective cisplatin-based therapies for ovarian cancer.


2018 ◽  
Vol 3 (2) ◽  
pp. 13
Author(s):  
Michelle Davis

Ovarian cancer is amongst the most life-threatening malignancy of the female reproductive system, whereas 90% of those ovarian cancers are epithelial with an overall poor five-year survival rate of 44% across all stages and all races [1]–[2], [31]. This paper aims to review the current treatment and diagnostic strategies for ovarian cancer [3]. Using grounded substantial research, multiple figures were developed to show the relations of ovarian cancer diagnostics and ovarian cancer therapeutics.  It is a great start to look into what may be causing most patients to become resistant to the current standard of care, platinum-based chemotherapeutics, for ovarian cancer [4]. A comprehensive literature review will be used to understand the genetic basis of the disease and possible cancer growth patterns, so we could possibly introduce better diagnostics and therapeutics [5]. The findings show that there are a variety of treatments options other than the standard of care, platinum-based therapy [6]. Nanoparticle encapsulation therapy is one way that has been approved by the FDA to therapeutically treat ovarian cancer without the platinum resistant side effects [7]. Also, the discovery of different diagnostics for ovarian cancer can help with better individualized treatments for patients with different forms of ovarian cancer [8]. Currently, the only serous diagnostic test for the detection of ovarian cancer is high levels of Cancer Antigen 125 (CA-125), which is only shown in 50% of early staged ovarian cancers [16]. The main treatment option for ovarian cancer is platinum-based drugs, in which most cases of patients with ovarian cancer will become resistant. Detecting and treating ovarian cancer while the cells are small, contained, and still in the early stages in vivo still remains to be a challenge [9]. Here, we will demonstrate the bioelectrical interactions of the ovarian cancer cells fused with the magnetic iron oxide nanoparticles with the use of an MRI. The findings demonstrate that the diagnostic method for the early detection of epithelial ovarian cancer requires the use of magnetic iron oxide nanoparticles with specific ligand external profiles as a contrast reagent to make the small-sized ovarian cancer cells appear more visible under MRI. 


Sign in / Sign up

Export Citation Format

Share Document